Noticias y Actividades de Ovid Therapeutics
Presencia
Ovid Therapeutics es una de las ...
Ovid Therapeutics es una empresa que cotiza bajo el símbolo de cotización OVID (US).
Ejecutivos
Ver el organigrama con sus 24 ejecutivos principales
Biografías más buscadas en Ovid Therapeutics
- Jeremy Levin, Chairman of the Board of Directors and Chief Executi...
- Barbara Duncan, Director
- Bart Friedman, Director
Recientes movimientos de ejecutivos en Ovid Therapeutics
- Danielle Mann, Vice President, Legal and Compliance, ha dejado la empresa (noticia publicada el 24 de marzo de 2025).
- Victoria Fort, se ha incorporado a la empresa como Head, Corporate Affairs and Corporate Strategy (noticia publicada el 13 de marzo de 2025).
- Stelios Papadopoulos, se ha incorporado a la empresa como Director (noticia publicada el 4 de marzo de 2025).
Haga clic aquí para ver otros movimientos en Ovid Therapeutics
Crear su alerta
para seguir los movimientos de los ejecutivos en Ovid Therapeutics.
Biotecnología
Ovid Therapeutics tiene 2.351 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Genus (Reino Unido).
Popular M&A news in Biotecnología
- Transcarent and Accolade have merged (publicado el 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 7 de abril de 2025).
- Atsena Therapeutics acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 4 de abril de 2025).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Ovid Therapeutics
- Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development Program | Ovid Therapeutics Inc.Email-press-release
- Ovid Therapeutics to Present at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) Virtual Congress | Ovid Therapeutics Inc.Email-press-release
- Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies | Ovid Therapeutics Inc.Email-press-release
- Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference | Ovid Therapeutics Inc.Email-press-release
- Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome | Ovid Therapeutics Inc.Email-press-release
- Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock | Ovid Therapeutics Inc.Email-press-release
- Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update | Ovid Therapeutics Inc.Email-press-release
- Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020 | Ovid Therapeutics Inc.Email-press-release
- Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome | Ovid Therapeutics Inc.Email-press-release
- Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe | Ovid Therapeutics Inc.Email-press-release
- View more press releases Close
Redes sociales sobre Ovid Therapeutics
- Ovid Therapeutics en Wikipedia, Google News y Yahoo Finance
- Ovid Therapeutics en LinkedIn, Twitter y YouTube
